Akums Drugs to host institutional investor meets in Mumbai on Sep 28-29
- Akums Drugs & Pharmaceuticals will hold institutional investor meetings on September 28 and 29, 2026
- Meetings are scheduled for 9:00 am onwards in Mumbai in physical mode
- No unpublished price sensitive information will be shared during the interactions
- Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015
*this image is generated using AI for illustrative purposes only.
Akums Drugs & Pharmaceuticals will participate in institutional investor meetings on September 28 and September 29, 2026, in Mumbai. The company announced the schedule in a filing to stock exchanges, specifying that these will be physical meetings involving multiple one-on-one and group sessions.
The meetings are scheduled to begin at 9:00 am (IST) on both days. Akums Drugs stated that no unpublished price sensitive information pertaining to the company will be shared with investors during these interactions.
Meeting Schedule Details
| Particulars | Date | Time | Mode | Location |
|---|---|---|---|---|
| Institutional Investor Meeting | September 28, 2026 | 9:00 am onwards | Physical | Mumbai |
| Institutional Investor Meeting | September 29, 2026 | 9:00 am onwards | Physical | Mumbai |
Regulatory Compliance and Disclaimers
The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dharamvir Malik, Company Secretary and Compliance Officer, signed the intimation on September 23, 2026.
The company noted that the schedule is subject to change due to exigencies on the part of investors or the company itself. A copy of this disclosure has been updated on the company's website.
Historical Stock Returns for Akums Drugs & Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.13% | +1.31% | +5.94% | +72.55% | +84.47% | +2.79% |
How might the insights gained from these institutional meetings influence Akums Drugs' stock valuation ahead of its upcoming quarterly earnings report?
Are there specific strategic partnerships or capacity expansion plans in the CDMO sector that investors are expected to probe during these sessions?
What impact could the outcome of these meetings have on the company's ability to secure long-term contracts with major global pharmaceutical clients?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
